Compare Hyatt Hotels Corporation (H) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hyatt Hotels Corporation vs Sana Biotechnology Inc — how do they compare? Hyatt Hotels Corporation trades at $161.78 (market cap $15.02B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: Hyatt Hotels Corporation is far larger — about 18× Sana Biotechnology Inc's market cap, and Hyatt Hotels Corporation pays a 0.38% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hyatt Hotels Corporation for 148 Days and Sana Biotechnology Inc for 23 Days on average.
| H | SANA | |
|---|---|---|
Market Cap | $15.02B | $836.71M |
Volume | 842,340 | 4,507,444 |
Sector | Consumer Cyclical | Health |
52-Week High | $202.09 | $5.92 |
52-Week Low | $135.42 | $2.68 |
Typical Hold Time | 148 Days | 23 Days |
Enterprise Value | $18.93B | $749.96M |
Dividend Yield | 0.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hyatt Hotels (H) trades at $161.75, up 2.93% with recent earnings beats driving momentum. The stock shows neutral technical signals with mixed moving averages and oscillators. Fundamentally, revenue grew to $7.1B in 2025 but net income turned negative at -$52M, while valuation metrics remain elevated with P/E at 196.83. Recent developments include strategic partnerships with Delta Air Lines and expansion of the Essentials portfolio.
Outlook remains cautiously optimistic with analyst consensus target of $197.77 (22% upside) but high valuation and negative cash flow trends pose risks. The company's growth initiatives and brand expansion provide opportunities, though investors should monitor debt levels and profitability recovery.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
